Evidence map›Paper›PMID 38979754›Full record

ArticleJournal of inherited metabolic disease2024

The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease.

Moritz Ilan Truninger, Helene Werner, Markus Andreas Landolt, Andreas Hahn, Julia B Hennermann, Florian B Lagler, Dorothea Möslinger, Charlotte Pfrimmer, Marianne Rohrbach, Martina Huemer

Abstract readValidation Study
In one paragraph

Article in Journal of inherited metabolic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. "Reading level is just one component": best practices for cognitive debriefing patient-reported outcome instruments with pediatric populations.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moritz Ilan TruningerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6724-5019
Helene WernerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7081-7695
Markus Andreas LandoltDepartment of Psychosomatics and Psychiatry, University Children's Hospital Zurich, Zurich, Switzerland.ORCID 0000-0003-0760-5558
Andreas HahnDepartment of Child Neurology, Justus-Liebig-University Gießen, Gießen, Germany.
Julia B HennermannVilla Metabolica, Center for Pediatric and Adolescent Medicine, University Medical Center Mainz, Mainz, Germany.
Florian B LaglerInstitute for Inherited Metabolic Diseases and Department of Pediatrics, Paracelsus Medical University Salzburg, Salzburg, Austria.
Dorothea MöslingerDepartment of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Charlotte PfrimmerDepartment of Child Neurology, Justus-Liebig-University Gießen, Gießen, Germany.
Marianne RohrbachDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Martina HuemerDivision of Metabolism, Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0590-678X

Funding

Sanofi
6 · The paper itself

Abstract

Genetic disorders pose great challenges for affected individuals and their families, as they must cope with the irreversible nature of the disease and a life-long dependence on medical assistance and treatment. Children and adolescents dealing with Pompe disease (PD) often struggle to keep up with their peers in physical activities. To gain valuable insights into their subjective experiences and better understand their perception and coping related to daily challenges linked to their condition and treatment, the use of standardized questionnaires is crucial. This study introduces the novel PompeQoL 1.0 questionnaire for children and adolescents with PD, designed for comprehensive assessment of both disease-specific FDH and HRQoL through self- and proxy reports. Content validity was ensured through patients' and parents' involvement at the initial stages of development and in subsequent cognitive debriefing process. Participants found the questionnaire easy to understand, answerable, relevant, and comprehensive. Adjustments based on feedback from patients and their parents improved its utility as a patient- and observer-reported outcome measure. After careful item examination, 52 items were selected, demonstrating moderate to excellent test-retest reliability for most scales and initial evidence for satisfactory construct validity. The PompeQoL questionnaire stands as a valuable screening instrument for both clinical and research purposes. Future research should prioritize additional revisions and larger validation studies, focusing on testing the questionnaire in clinical practice and trials. Nevertheless, the PompeQoL 1.0 stands out as the first standardized measure providing insights into disease-specific FDH and HRQoL among children and adolescents with various forms of PD.

Indexed as

Glycogen Storage Disease Type IIQuality of LifeAdolescentChildFemaleHumansMaleParentsPsychometricsReproducibility of ResultsSurveys and Questionnairesfunctioning, disability, and healthhealth‐related quality of lifeInstrumentobserver‐reported outcomepatient‐reported outcomepediatric patientsproxy reportself‐report

Identifiers

PMID38979754
PMCPMC11586600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.